Interaction Checker
No Interaction Expected
Dolutegravir/Lamivudine (DTG/3TC)
Estradiol
Quality of Evidence: Very Low
Summary:
Coadministration with estradiol as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estradiol is metabolized by CYP3A4, CYP1A2 and is glucuronidated. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine. Preliminary data with estradiol administered as feminizing hormone therapy (FHT) to trans women with HIV taking FHT and integrase inhibitors (bictegravir/emtricitabine/tenofovir alafenamide, n=8; dolutegravir/abacavir/lamivudine, n=2) suggest a low probability of clinically relevant drug-drug interactions between FHT and unboosted integrase inhibitor-based ART.
Description:
View all available interactions with Dolutegravir/Lamivudine (DTG/3TC) by clicking here.
Copyright © 2026 The University of Liverpool. All rights reserved.